Therapeutics Uses of Psychedelics in patients with psychiatric disorders A Systematic Review
Sarosh Nawaz, Abdulaziz Mohammed Althwanay, B Esraa M. Aledani Mb Ch, Harleen Kaur, Malik Kasapoglu, Rajesh Yadavalli, Ann Kashmer Yu
Journal For International Medical Graduates April 18, 2024 DOI: 10.56570/jimgs.v1i1.155 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Randomized Peer reviewed |
|---|---|
| Topics | Anxiety LSD Mescaline Psilocybin |
| Keywords | Hallucinogen Mood Psychotherapist Clinical psychology |
| Key findings | Psychedelics show potential as a treatment option for psychiatric disorders, with evidence from pilot studies and randomized controlled trials indicating effective improvement in conditions like depression, anxiety, PTSD, and cancer-related existential distress. |
Abstract
The impact of psychedelic treatment on patients suffering from psychiatric diseases like depression, anxiety, post-traumatic psychiatric disorder (PTSD), and existential distress related to cancer has become very intriguing to psychiatrists in the modern era. Serotonergic psychedelics include Lysergic acid diethylamide (LSD), psilocybin, mescaline, ayahuasca, and methylene-deoxy methamphetamine (MDMA) which act agonistically on 5-hydroxytryptamine type 2-A (5-HT2A) receptors. Psychedelics produce a wide range of effects, based on varying sites of 5-HT2a receptors, including changes in consciousness, perception, mood, and behaviour. Psychedelics can lead to both good and bad trips depending on the dose and environment in which it is taken. We used systematic approach by strictly following Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 2020 guidelines. Data is extracted from pub med using mesh strategy, and from google scholar and science direct by using keywords. 10 review articles are selected by using quality appraisal tools. The purpose of this paper is to highlight the mechanism of action and role of psychedelics in patients with mental health disorders. In this review, we discussed the effective models of neurodynamical changes produced by psychedelics, and we also show that these substances can be used as a potential treatment option for psychiatric patients. Psychedelics have shown effective improvement in psychiatric diseases in many pilot studies and randomized controlled trials. There is still a debate going on about which models best suggest their role in the field of psychiatry.
Comparable studies
Other systematic reviews and meta-analyses on LSD for anxiety, most cited first.
Citations in the library
Cites 15
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
and 10 more in the library